Navigation Links
Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R) NCD as a Combination Therapy for Glioblastoma Multiforme

ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announces the presentation of results of a single-agent Phase 2 study for Panzem(R) NCD (2ME2) in patients with glioblastoma multiforme (GBM). The data were presented by David A. Reardon, M.D., Associate Deputy Director at The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center and principal investigator for the study, at the American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago.

The single-agent, open-label study, conducted at Duke University, was designed to assess the safety, pharmacokinetics and efficacy of Panzem(R) NCD in patients with recurrent GBM who have failed initial therapies. Of the 27 patients enrolled in this study, 78% had received two or more prior cancer agents. Results from this Phase 2 study included one partial response and seven stable diseases. Panzem(R) NCD was well-tolerated with reversible transaminase elevations as the only grade 3 toxicity in more than one patient, and no grade 4 toxicities.

Commenting on the results of the study, Dr. Reardon said, "Panzem(R) NCD was generally well-tolerated and showed modest activity as a single agent. This study and prior preclinical studies support the hypothesis that Panzem(R) NCD could be used in combination with an approved chemotherapeutic agent such as temozolomide (Temodar(R)) in GBM patients to potentially improve outcome further. The Duke University Brain Tumor Center has recently initiated a Phase 2 study of the Panzem(R) NCD/Temodar(R) combination."

Carolyn F. Sidor, M.D., MBA, EntreMed Vice President and Chief Medical Officer, commented, "Our clinical developme
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
(Date:7/14/2014)... July 14, 2014 Felicity Philp was diagnosed ... 29 years old. Instead of letting her health issues decrease ... food she was eating and began to see a difference ... two friends and business partners, Julie Reardon and Kate Owen, ... help others with this lifestyle change as well. In their ...
(Date:7/14/2014)... Georgia State University is starting four new ... round of its Second Century Initiative, aiming to ... performance. , The Second Century Initiative (2CI) ... to the university, with the goal of building ... significance. , “With the fifth round of the ...
(Date:7/14/2014)... , Scientists funded by the National Institutes of Health ... esophagitis (EoE), an inflammatory disease characterized by high ... Their findings suggest that several genes are involved in ... and often is associated with food allergies. The findings ... the esophagus. The work was supported in part by ...
(Date:7/14/2014)... PA, July 14, 2014 The inability to ignore ... often experienced by individuals diagnosed with schizophrenia, reports a ... Psychiatry . , Our brains are usually good at ... learn and filtering out the "noise" or thoughts that ... related in part to a problem with this filtering ...
(Date:7/14/2014)... Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 ... York (RGONY), with offices in Hicksville and Hauppauge, ... intravitreal implant) as a long-lasting treatment for diabetic ... by Allergan, recently obtained an additional FDA-approved indication ... previously approved by the FDA in 2009 for ...
Breaking Medicine News(10 mins):Health News:Women Changing Lives Through Food 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:Scientists deepen genetic understanding of eosinophilic esophagitis 2Health News:'Noisy' memory in schizophrenia 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3
... ... ... ... ...
... who have both diabetes and major depression are more than ... diabetes only, according to a study published in the recent ... the progressive decline of thinking and reasoning abilities. These can ... the past, personality changes, and not recognizing familiar people. ...
... researchers say , FRIDAY, March 5 (HealthDay News) -- Freezing ... mice, a new study has found. , Researchers tested two ... applying a cold probe to the tumor, but one method ... the other takes a few minutes. The mice that received ...
... ... ... ... ...
... , ... ... ... ...
... report released today by Rice University,s Jones Graduate School of ... since October 2009, current Toyota owners are not yet wavering ... The rigorous survey-based study of a national sample ... satisfaction with their vehicles, quality was equally high among Toyota ...
Cached Medicine News:Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 2Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 3Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 4Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 5Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 6Health News:Major depression more than doubles risk of dementia among adults with diabetes 2Health News:Major depression more than doubles risk of dementia among adults with diabetes 3Health News:Freezing Technique May Stop Breast Cancer 2Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 2Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 3Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 4Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 5Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 6Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 2Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 3Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 4Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 5Health News:Survey: Toyota owners maintain high overall satisfaction despite recalls 2
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: